July 15, 2015

Galectin Therapeutics Inc. Appoints Adam E. Allgood, Pharm.D., R.Ph., as Executive Director of Clinical Development

NORCROSS, Ga., July 15, 2015 (GLOBE NEWSWIRE) -- **Galectin Therapeutics Inc.** (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced the appointment of Adam E. Allgood, Pharm.D., R.Ph. as executive director of clinical development, effective immediately. Dr. Allgood is an experienced industry professional with more than 28 years of pharmaceutical industry experience in effectively designing, implementing, monitoring, and directing clinical programs in all four phases of clinical development, ranging from Phase 1 first-in-human trials to large global Phase 3 clinical trials and post marketing trials. His therapeutic expertise spans a variety of therapeutic areas including gastroenterology, and encompasses clinical trial leadership, key opinion leader interface, significant contract research organization management experience, clinical trial investigator training, and clinical advisory board responsibilities. In addition, Dr. Allgood has extensive clinical research and/or regulatory experience in immunology, rheumatology, neurology, and women's health.

"Adam is an excellent addition to our team as he brings a broad range of clinical development experience, including a track record of success in designing, executing and successfully completing clinical studies. He joins Galectin at a critical time as the Company has started a multi-trial Phase 2 clinical development program focused on the use of GR-MD-02 for treatment of non-alcoholic steatohepatitis (NASH) in patients with fibrosis and cirrhosis. Adam will be an important part of the team as we work to deliver on the promise of a treatment for this common and deadly disorder," said Peter G. Traber, M.D., president, chief executive officer, and chief medical officer of Galectin.

"I welcome the opportunity to join the Galectin team in its exciting endeavor to develop GR-MD-02 to its full potential for impacting the lives of patients who suffer from severe diseases such as NASH, other fibrotic organ conditions, and cancer," added Dr. Allgood. "I look forward to contributing to Galectin's already extensive and impressive scientific, development, and regulatory expertise focusing on developing galectin inhibitors to fill the continuing significant unmet medical need for effective treatments for these serious and life-threatening diseases."

Dr. Allgood most recently was associate director of global pharmaceutical regulatory affairs at UCB Inc., a multinational biopharmaceutical company. His prior positions include leadership roles at Abbott Laboratories and Solvay Pharmaceuticals in regulatory affairs, clinical development and medical affairs.

Dr. Allgood earned his Doctor of Pharmacy (Pharm.D.) degree *summa cum laude* from Mercer University College of Pharmacy and Health Sciences in Atlanta and is a Registered Pharmacist (R.Ph.). He is a member of the American Pharmacists Association (APHA), the Georgia Pharmacy Association (GPHA), and the Association of the United States Army (AUSA).

About Galectin Therapeutics

Galectin Therapeutics (NASDAQ:GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, key mediators of biologic function. We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer. Additional information is available at www.galectintherapeutics.com.

Forward-Looking Statements

This press release contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as "may," "estimate," "could," "expect" and others. They are based on our current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those described in the statements. Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include, among others: incurrence of operating losses since our inception, uncertainty as to adequate financing of our operations, extensive and costly regulatory oversight that could restrict or prevent product commercialization, inability to achieve commercial product acceptance, inability to protect our intellectual property, dependence on strategic partnerships, product competition, and others stated in risk factors contained in our SEC filings. We cannot assure that we have identified all risks or that others may emerge which we do not anticipate. You should not place undue reliance on forward-looking statements. Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements.

CONTACT: Galectin Therapeutics Inc.

Peter G. Traber, M.D.

President, CEO & CMO

(678) 620-3186

ir@galectintherapeutics.com

LHA

Kim Golodetz

(212) 838-3777

kgolodetz@lhai.com

Source: Galectin Therapeutics, Inc.